Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Lessons From Lockdown: Hepatitis Delta Elimination Strategies in the COVID-19 Era

In this engaging dialogue, 2 expert hepatologists discuss strategies to maintain and improve screening and testing for hepatitis delta virus in the COVID-19 era.
Robert G. Gish, MD
person default
Pietro Lampertico, MD, PhD
Released: February 11, 2022

In this episode, Robert G. Gish, MD, and Pietro Lampertico, MD, PhD, share lessons learned in the care of patients coinfected with hepatitis B virus and hepatitis delta virus (HDV), including:

  • Burden of HDV infection
  • Chronic HDV infection and comorbidities
  • Impact of COVID-19 on care of patients with chronic hepatitis B
  • Screening for HDV and which assays to use
  • Screening for viral hepatitis at a COVID-19 vaccination site

Information on this Educational Activity

Faculty

Robert G. Gish, MD

Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno School of Medicine
Clinical Professor
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director

Hepatitis B Foundation
Washington, DC

Robert G. Gish, MD, has disclosed that he has received funds for research support from Gilead Sciences; has received consulting fees from Abbott, AbbVie, Altimmune, Antios, Arrowhead, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Pfizer, Salix, Shionogi, Topography Health, Venatorx, and Viking; has served on advisory boards for Abbott, AbbVie, Altimunne, Antios, Arrowhead, Bristol-Myers Squibb, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTx, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Pfizer, Salix, Shionogi, Venatorx, and Viking; and has served on data and safety monitoring boards for Altimmune, Arrowhead, CymaBay, and Durect.
Pietro Lampertico, MD, PhD

Professor of Gastroenterology
Director, Division of Gastroenterology and Hepatology
IRCCS Ca Granda Policlinico Hospital
University of Milan
Milan, Italy

Pietro Lampertico, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Aligos, Antios, Eiger, Gilead Sciences, GlaxoSmithKline, Janssen, and Myr Pharma.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by:
AbbVie
Gilead Sciences, Inc.

Related Content

Dr Stefan Zeuzem discusses his take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Stefan Zeuzem, MD Released: December 5, 2022

Dr Nancy Reau discusses her take on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 2, 2022

Prof George Lau: proactive monitoring and treatment are necessary for all patients with CHB, regardless of age, from Clinical Care Options (CCO)

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: December 1, 2022

Expert summaries of AASLD, EASL, APASL guidance on monitoring and treating chronic hepatitis B and delta infections, with Maria Buti, Paul Kwo, Grace Wong

Maria Buti, MD Paul Y. Kwo, MD Grace LH Wong, MD Released: December 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings